Published in J Psychiatr Res on September 01, 1972
Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry (2008) 1.57
The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments. Pharmaceuticals (Basel) (2010) 0.76
The effect of mianserin on urinary catecholamine excretion in psychiatric patients. Br J Clin Pharmacol (1981) 0.75
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol (1995) 8.09
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A (2001) 7.15
Regulation of adipose tissue pyruvate dehydrogenase by insulin and other hormones. Biochem J (1971) 4.50
Stimulation by calcium ions of pyruvate dehydrogenase phosphate phosphatase. Biochem J (1972) 4.05
Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A (1999) 3.54
Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res (1996) 3.03
Improved lactose digestion and intolerance among African-American adolescent girls fed a dairy-rich diet. J Am Diet Assoc (2000) 2.94
Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther (1996) 2.90
Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med (1999) 2.72
The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther (1994) 2.55
Induction of maternal behavior in virgin rats after intracerebroventricular administration of oxytocin. Proc Natl Acad Sci U S A (1979) 2.43
Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther (1993) 2.40
Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther (2000) 2.26
Oxytocin induces maternal behavior in virgin female rats. Science (1982) 2.23
Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol (2001) 2.22
Role of adenine and guanine nucleotides in the activity and response of adenylate cyclase systems to hormones: evidence for multisite transition states. Adv Cyclic Nucleotide Res (1975) 2.06
Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotine withdrawal signs. J Pharmacol Exp Ther (2008) 2.04
Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem (2000) 2.04
Mechanisms regulating adipose-tissue pyruvate dehydrogenase. Biochem J (1972) 2.01
Selective release of newly synthesized norepinephrine from the cat spleen during sympathetic nerve stimulation. J Pharmacol Exp Ther (1968) 1.99
Continuous infusion of pyridostigmine in the management of myasthenic crisis. Crit Care Med (1993) 1.99
Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J Pharmacol Exp Ther (1998) 1.97
Cannabis: pharmacology and toxicology in animals and humans. Addiction (1996) 1.89
Distinct patterns of DeltaFosB induction in brain by drugs of abuse. Synapse (2008) 1.87
Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther (1997) 1.87
Metabolism of normetanephrine-H3 in rat brain--identification of conjugated 3-methoxy-4-hydrophenylglycol as the major metabolite. Biochem Pharmacol (1968) 1.86
In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther (1996) 1.85
p-Chlorophenylalanine-induced chemical manifestations of phenylketonuria in rats. Science (1967) 1.82
Nicotine dependence and reward differ between adolescent and adult male mice. J Pharmacol Exp Ther (2007) 1.81
Subclinical hypothyroidism: a modifiable risk factor for depression? Am J Psychiatry (1993) 1.78
Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther (1992) 1.76
Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature (1997) 1.76
Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension (1997) 1.75
3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem (1999) 1.73
Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol (1995) 1.72
Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons. J Pharmacol Exp Ther (1970) 1.69
3-methoxy-4-hydroxyphenylglycol sulfate in brain and cerebrospinal fluid. Biochem Pharmacol (1968) 1.64
Characterization of spontaneous and precipitated nicotine withdrawal in the mouse. J Pharmacol Exp Ther (2003) 1.64
Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther (1988) 1.58
Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther (1996) 1.55
Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug Alcohol Depend (2000) 1.55
Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212. J Pharmacol Exp Ther (1994) 1.52
A hypothesis of thyroid-catecholamine-receptor interaction. Its relevance to affective illness. Arch Gen Psychiatry (1981) 1.49
A simple enzymic method for the synthesis of adenosine 5'-[alpha-32P]triphosphate on a preparative scale. Biochem J (1977) 1.47
Evidence that the antinociceptive tail-flick response is produced independently from changes in either tail-skin temperature or core temperature. Pain (1993) 1.46
Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther (1992) 1.41
An experimental study in the treatment of narcotic addicts with cyclazocine. Clin Pharmacol Ther (1966) 1.40
Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J Pharmacol Exp Ther (2005) 1.39
Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology (Berl) (1995) 1.38
Localization of D1 dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission. Proc Natl Acad Sci U S A (1991) 1.38
Cost and survival results of critical care regionalization for Medicare patients. Crit Care Med (1989) 1.37
Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther (1998) 1.37
Pharmacokinetics of methylphenidate in man, rat and monkey. J Pharmacol Exp Ther (1983) 1.36
Novel approach to investigate a source of microbial contamination of central venous catheters. Eur J Clin Microbiol Infect Dis (1997) 1.36
Cannabinoid tolerance and dependence. Handb Exp Pharmacol (2005) 1.35
Metabolism of tyramine-3H and octopamine-3H by rat brain. Biochem Pharmacol (1969) 1.35
Insulin inhibits the cholera-toxin-catalysed ribosylation of a Mr-25000 protein in rat liver plasma membranes. Biochem J (1985) 1.35
Effects of thyrotropin-releasing hormone in depression. Lancet (1972) 1.34
Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo. Proc Natl Acad Sci U S A (1996) 1.32
Racial differences in bone turnover and calcium metabolism in adolescent females. J Clin Endocrinol Metab (2003) 1.31
Insulin activates pyruvate dehydrogenase in rat epididymal adipose tissue. Nat New Biol (1971) 1.31
Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes. J Pharmacol Exp Ther (1998) 1.31
Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine. Br J Pharmacol (1971) 1.31
Thyrotropin releasing hormone: enhancement of dopa activity by a hypothalamic hormone. Science (1972) 1.31
Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol Pharmacol (1992) 1.30
Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Eur J Pharmacol (1999) 1.30
Multiple withdrawals from chronic ethanol "kindles" inferior collicular seizure activity: evidence for kindling of seizures associated with alcoholism. Alcohol Clin Exp Res (1990) 1.30
Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin. Nature (1976) 1.29
Effects of morphine, nalorphine, cyclazocine, and naloxone on the flexor reflex. Int J Neuropharmacol (1967) 1.29
Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol (2001) 1.29
Induction of Fos-like proteins and ultrasonic vocalizations during ethanol withdrawal: further evidence for withdrawal-induced anxiety. Alcohol Clin Exp Res (1998) 1.28
Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys. J Pharmacol Exp Ther (1995) 1.28
The antinociceptive effects of alpha7 nicotinic agonists in an acute pain model. Neuropharmacology (2000) 1.28
Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther (2001) 1.27
Metabolism of pyruvate and malate by isolated fat-cell mitochondria. Biochem J (1971) 1.26
Effects of acute and chronic 1,3-butanediol treatment on central nervous system function: a comparison with ethanol. J Pharmacol Exp Ther (1981) 1.26
Effects of insulin and adrenaline on rat epididymal-fat-pad pyruvate dehydrogenase. Biochem J (1971) 1.26
Delta 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology (Berl) (1996) 1.25
Neuroanatomical characterization of Fos induction in rat behavioral models of anxiety. Brain Res (1996) 1.24
The biodisposition and metabolism of anandamide in mice. J Pharmacol Exp Ther (1997) 1.24
Mental changes accompanying thyroid gland dysfunction. A reappraisal using objective psychological measurement. Arch Gen Psychiatry (1969) 1.24
Flumazenil blockade of anxiety following ethanol withdrawal in rats. Psychopharmacology (Berl) (1997) 1.24
Soy isoflavones do not affect bone resorption in postmenopausal women: a dose-response study using a novel approach with 41Ca. J Clin Endocrinol Metab (2006) 1.24
Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology. J Clin Endocrinol Metab (2009) 1.22
Antinociceptive responses to nicotinic acetylcholine receptor ligands after systemic and intrathecal administration in mice. J Pharmacol Exp Ther (1998) 1.22
Abnormalities of indoleamines in affective disorders. Arch Gen Psychiatry (1972) 1.20
Pharmacology of the enantiomers of threo-methylphenidate. J Pharmacol Exp Ther (1987) 1.19
Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders. Am J Psychiatry (1982) 1.19
Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem (1996) 1.19
The effect of insulin on plasma-membrane and mitochondrial-membrane potentials in isolated fat-cells. Biochem J (1981) 1.19
Pharmacological specificity of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rhesus monkeys. Drug Alcohol Depend (1995) 1.18